Evolution of the Average Target: UCB

Data source: UCB(UCB)

Evolution of the Target Price: UCB

Data source: UCB(UCB)

Changes in Analyst Recommendations: UCB

Data source: UCB(UCB)
6b64e418025d25d7.j7tJbeKMKkZ0IU-MUosw0pcxBml87I3StTziEhySMlI.xP9_OajAcwc9ET3-FNxVtd1cZSIjv9mT8n6kWnPqQ2Tiin8FsfVTMydRIA~ca79fe42c0d3a38d0e067d8e864d894f
09-24 BofA Reaffirms UCB at Buy Amid 'Very Confident' Outlook for Psoriasis Drug MT
09-24 BofA Securities Keeps UCB at Buy MT
09-11 AlphaValue/Baader Europe Sees UCB Share Drop as 'Rare Window of Affordability'; Price Target Up MT
09-10 UCB: A rare window of affordability Alphavalue
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-18 UCB: An unimpressive upgrade-led correction opens a rare opportunity Alphavalue
08-11 Berenberg Adjusts UCB Forecasts After H1 Beat; Buy Reaffirmed MT
08-11 UCB barely moves despite positive calls from ING and Berenberg Zonebourse
07-31 AlphaValue/Baader Europe Upgrades UCB to Add, Trims PT MT
07-30 Kempen Upgrades UCB to Buy Rating, Boosts PT MT
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-03 Berenberg Updates Price Target, Estimates for UCB on Recent Pipeline Deals MT
06-22 UBS Trims UCB's PT, Affirms Buy Rating MT
06-15 UCB Slumps Following Analyst Downgrade Zonebourse
06-15 Barclays Downgrades UCB to Equalweight, Trims PT MT
06-15 UCB Kept at Buy as BofA Notes Psoriasis Drug Momentum MT
06-09 UCB Favored by Oddo BHF Zonebourse
06-05 KBC Securities Maintains Buy Rating on UCB Zonebourse
05-21 UCB Price Target, Estimates Up as AlphaValue/Baader Europe Notes Growth Momentum MT
05-20 UCB: Executing well, but valuation lacks safety net Alphavalue
04-27 AlphaValue/Baader Europe Upgrades UCB to Reduce, Trims PT MT
03-30 MoonLake Trial Data Continue to Support Efficacy of Sonelokimab to Treat Hidradenitis Suppurativa, Wedbush Says MT
03-16 Berenberg says Belgian drugmaker UCB stock is undervalued Zonebourse
03-16 Berenberg Keeps UCB Amid Positive Pipeline Progress, H2 Catalysts MT
02-26 UCB: H2 beat; 2026 outlook healthy; but valuation remains red-hot Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+16.27%
+9.08%
+6.1%
+7.94%
+8.57%
+8.14%
+34.02%
-3%
+9.61%
Average +10.75%
Weighted average by Cap. +11.42%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
204.30EUR
Average target price
285.00EUR
Spread / Average Target
+39.50%
High Price Target
340.00EUR
Spread / Highest target
+66.42%
Low Price Target
208.00EUR
Spread / Lowest Target
+1.81%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
AA